Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cell Transplant for AML in Second Remission
NCT00002768Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 1996
- Primary completion
- Feb 2003
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous peripheral blood stem cell in acute myeloid leukemia (AML), sponsored by Cancer and Leukemia Group B. Primary endpoint: Disease-free survival at 2 years. Started Jun 1996; status: completed.
02
Drugs
autologous peripheral blood stem cell
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00002768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002768.